In the past 10 years of clinical work, more than 150 cases of peripheral facial palsy have been treated, but only 2 cases of recurrent peripheral facial palsy have been seen, with a disease duration of several years. syndrome cases have also been reported in the literature. Treatment: Hormonal therapy is still used, and most of the reported cases are in remission, with a few cases treated with surgical decompression. I. Recent literature excerpts on Mero syndrome (2014): Mero syndrome is a rare neuromucosal granulomatosis of unknown cause characterized by facial palsy, lingual fissures, and orofacial edema, and there are very few reports of Mero syndrome with facial nerve palsy as the main manifestation in more than 20 patients. A review reported cases diagnosed with Mero syndrome at our University Facial Nerve Center. There were only 21 cases from 1997-2010. The age of onset ranged from 22-67 years, with a mean age of 44.1 years. 7 (33.3%) patients were male and 14 (66.7%) were female. All cases had facial palsy. 14 (66.7%) patients initially presented with unilateral facial palsy and subsequently developed contralateral facial palsy (alternating facial palsy). 1 patient presented with simultaneous bilateral facial palsy. The number of episodes per patient ranged from 1-8 (mean 3.1). 35 episodes were on the right side and 31 on the left side. Most of the patients with recurrent attacks had 4 attacks on the left side and 4 on the right side. The three patients followed up had 6 episodes on each side. The age of first occurrence of facial nerve palsy ranged from 2-60 years (mean 34.4, median 39). The mean interictal interval was 4.7 years (from 0-30, median 3). 6 patients had a family history of Mero syndrome. Mero syndrome is a rare disease of unclear etiology. Patients may present with different symptoms and are usually not in the classical triad. In our cases of facial palsy diagnosed as Mero syndrome, the proportion of triadic syndrome was higher than previously reported. II. guidelines for the treatment of facial neuritis (Bell’s palsy) (2013) 1. clinicians should exclude specific etiologies of facial palsy by history and examination; 2. clinicians should not routinely perform laboratory tests in patients with new-onset Bell’s palsy; 3. clinicians should not routinely perform imaging studies in patients with new-onset facial neuritis; 4. clinicians should use oral examination in patients aged 16 A. Clinicians should not use oral hormone therapy alone to treat new-onset facial neuritis within 72 hours of onset, and the total dose of prednisone should exceed 450 mg. (Note: 60 mg*5 days, followed by a daily reduction of 10 mg for a total of 10 days; or 50 mg*10 days); 5. A, physicians should not perform electrophysiological examinations for facial neuritis with incomplete facial palsy; 7. 9. No data are available to recommend acupuncture for facial neuritis; 10. No data are available to recommend physical therapy for the facial nerve; 11. Physicians should reevaluate or refer to a facial nerve specialist for patients with new or worsening neurologic deficits at any time, patients with ocular symptoms at any time, or patients who have not fully recovered after 3 months of onset. consultation.